Ascend Wellness (AAWH) reported $501M in revenue for fiscal 2025, −10.9% year on year. That ranks #2210 by revenue among 2853 SEC filers and #217 in Healthcare. It posted a net loss of −$118M for the same year. Revenue has grown 86.1% a year on average since 2019 ($12.0M then). The fiscal 2025 balance sheet shows $908M in total assets, $85.7M in cash and $291M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $501M | −10.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $170M | −7.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$17.0M | −$21.7M | FY20252025-12-31 |
| Net incomeProfitLoss | −$118M | −$33.2M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $38.1M | −48.1% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $26.0M | +15.4% | FY20252025-12-31 |
| Total assetsAssets | $908M | +0.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$47.4M | −$118M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $85.7M | −2.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $291M | +35.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $117M | −$29.5M | Open → |
| Q2 20262026-06-30 | $126M | −$9.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ascend Wellness Holdings, Inc.
- Ticker
- AAWH
- Exchange
- OTC
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 12-31
- CIK
- 0001756390
Filings
- 10-QAug 12, 2026Open filing →
- 10-QMay 13, 2026Open filing →
- 10-KMar 12, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| GlaukosGKOS | $507M | −$188M |
| Starling OncologySTLN | $503M | $60.6M |
| Bridgebio PharmaBBIO | $502M | −$733M |
| Ascend WellnessAAWH | $501M | −$118M |
| Travere TherapeuticsTVTX | $491M | −$25.5M |
| Porch GroupPRCH | $482M | −$3.4M |
| Natures Sunshine ProductsNATR | $480M | $19.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascend Wellness — Key figures |url=https://companiesranked.com/en/company/ascend-wellness |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascend Wellness — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ascend-wellnessBibTeX
@misc{companiesranked-en-company-ascend-wellness-2026,
author = {{CompaniesRanked}},
title = {{Ascend Wellness — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascend-wellness}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-017374 · March 12, 2026
{{cite web |title=Ascend Wellness — Key figures — 10-K (0001628280-26-017374) |url=https://www.sec.gov/Archives/edgar/data/1756390/000162828026017374/aawh-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.